Discussion
In this study, a dynamic nomogram is developed to predict the individual risk of AKI in CAP patients. To the best of our knowledge, this is the first study to develop a convenient and practical dynamic nomogram for predicting AKI in CAP patients. This dynamic nomogram includes albumin, acute respiratory failure, CURB-65, Cystatin C and white cell count, making it an objective, visual and simple-to-use screening tool for AKI in CAP patients. A dynamic nomogram based on a user-friendly digital interface responding in a dynamic online manner to personalised medicine may help support better clinical decision-making. Furthermore, the dynamic nomogram shows good discriminatory ability, calibration performance and clinical efficacy for predicting AKI in CAP patients.
The incidence of AKI was 28.7%, similar to the incidence rates reported by other studies.3 4 6 7 Murugan et al reported that 34.4% of patients developed AKI in the multicentre prospective cohort study of 1836 patients hospitalised with CAP.3 Akram et al reported that the incidence rate of AKI on admission in CAP patients was 18%.4 Latief et al observed in a prospective observational study that 27.6% of CAP patients had AKI.6 A previous study reported that the incidence of AKI was as high as 16%–25% in patients with non-severe pneumonia.7 As AKI has a poor impact on both short-term and long-term prognosis in CAP patients, several studies have investigated the risk factors for AKI in CAP patients.4 5 8 Independent factors associated with AKI reported in these patients include age, male gender, comorbidity (such as chronic kidney disease, hypertension, diabetes and cardiac dysfunction), blood parameters (C reactive protein, interleukin-6, tumour necrosis factor and lactate dehydrogenase), acute respiratory failure, drugs (such as statins, ACE inhibitors, angiotensin-II-receptor blockers, diuretics and vasoactive drugs), and severity scoring systems of pneumonia (Pneumonia Severity Index19 and CURB-65).3–7 Albumin, Cystatin C, white cell count, CURB-65 and acute respiratory failure were identified as five independent factors associated with AKI in CAP patients in our study. Acute respiratory failure and CURB-65 have been identified as predictors for AKI in CAP patients in previous studies.5 6 Although white cell count, albumin and Cystatin C have not been reported as independent factors for AKI in CAP patients, they have been reported as predictors for AKI in other clinical settings.20–25 We discovered that Cystatin C is the most important predictor for AKI in CAP patients, and a one-unit (1 mg/L) increment in Cystatin C is associated with a 5.42-fold increased risk of AKI.
Although several studies have investigated predictors for the early detection of AKI in CAP patients, few have been applied in clinical practise. This is the first study to use a convenient and practical dynamic nomogram to predict AKI in CAP patients. To apply the dynamic nomogram in clinical practise, we developed a clinician-friendly and online dynamic nomogram (https://cap-aki.shinyapps.io/cap-aki/). By entering the relevant values of predictors in the interactive interface and clicking the ‘Predict’ button, a dynamic nomogram displayed a graphical representation of the probability of the predicted AKI risk. Additionally, by clicking on the ‘Numerical summary’ button, it showed specific probabilities and 95% confidence intervals. The dynamic nomogram model shows good discrimination with an AUC of 0.870 (sensitivity=85.3% and specificity=76.4%) and good calibration with a Brier score of 0.129. Moreover, decision curve analysis reveals that the dynamic nomogram prediction model is clinically useful. The dynamic nomogram was more intuitive and convenient in its actual application due to the result’s visualisation. However, the predicted results of the dynamic nomogram were for reference only and should not be used as the sole basis for decision-making. Doctors also needed to make decisions based on clinical experience and other professional knowledge.
However, this study is not devoid of limitations. First, the dynamic nomogram for AKI in patients with CAP was fit in a single-centre retrospective cohort, and the generalisability and predictive accuracy need to be validated in a prospective multicentre cohort. Second, according to KDIGO criteria, the diagnosis of AKI is typically based on the SCr and urine output levels.12 However, due to the unavailability of urine output data, the definition of AKI according to the urine output standard is not included in our analysis. Third, some novel biomarkers (such as proenkephalin, Dickkopf-3, and C-C motif chemokine ligand 14) have been recently identified and applied to predict AKI.26–30 If these novel biomarkers are combined, the predictive performance of the model may be further enhanced. Fourth, AKI is commonly encountered in patients with decompensated cirrhosis. As this is a retrospective study, we lack data on liver disease in this model.31 Fifth, although we find that Cystatin C is an important biomarker for predicting AKI in the model, Cystatin C may not be widely used in some areas, which may limit the application of the dynamic nomogram.
In conclusion, our study uses a dynamic nomogram established from five independent predictive factors (Cystatin C, CURB-65, albumin, acute respiratory failure and white cell count) to predict the risk of AKI in CAP patients. Patients at high risk of AKI may benefit from this clinical tool through early detection and timely intervention.